StockNews.AI

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

StockNews.AI • 3 hours

GENECRMDADCT
High Materiality10/10

Information

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac...

Original source

AI Summary

IN8bio's DeltEx™ Drug-Resistant Immunotherapy γδ T cells demonstrate a 97% improvement in median progression-free survival, reaching 13 months, while median overall survival increased to 17.2+ months. These compelling results showcase the therapy's potential to revolutionize treatment for glioblastoma, leading to possible accelerated FDA approval. Investors should closely monitor INAB for positive price movement ahead.

Sentiment Rationale

The substantial improvement in progression-free and overall survival rates represents a breakthrough in GBM treatment, akin to other successful oncology therapies. Historical precedents show that similar advancements can lead to major stock rallies.

Trading Thesis

INAB is a strong buy due to breakthrough clinical data, targeting short-term gains.

Market-Moving

  • Investors could expect a price spike following positive FDA dialogue.
  • Increased institutional investment likely as trial results are validated.
  • Market sentiment could shift favorably with potential for accelerated approval.
  • Compelling survival data might lead to strategic partnerships or licensing agreements.

Key Facts

  • DeltEx DRI therapy nearly doubled mPFS to 13 months.
  • Median overall survival for DeltEx DRI patients is currently 17.2+ months.
  • 57% of patients remained progression-free longer than expected.
  • No severe adverse events reported in DeltEx DRI study.
  • Funding will support FDA discussions for potential accelerated approval.

Companies Mentioned

  • IN8bio (INAB): Positive trial results could lead to stock price increase.

Corporate Developments

This news fits under 'Corporate Developments' as it highlights significant advancements in INAB's product pipeline, factors likely to influence market perception and investor interest significantly.

IN8bio Reports Promising Data on Glioblastoma Treatments with DeltEx™ γδ T Cell Therapy

Posted on January 12, 2026

Key Clinical Findings Presented

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, has announced significant advancements in its ongoing trials for the treatment of newly diagnosed glioblastoma (GBM). Recent data from the INB-200 Phase 1 and INB-400 Phase 2 trials reveal that its investigational therapy, DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (referred to as DeltEx DRI), has nearly doubled the median progression-free survival (mPFS) rate, achieving a remarkable 13.0 months compared to the traditional standard-of-care (SOC) Stupp protocol, which averages 6.6 months.

Clinical Data Summary

The updated data, which was first presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, shows that the median overall survival (mOS) for patients receiving DeltEx DRI is currently over 17.2 months, with several individuals remaining progression-free for periods ranging from 1.4 to 4.6 years. In contrast, those undergoing SOC treatment have a final mOS of 13.2 months.

Impressive Results in Treatment Cohorts

  • Median Progression-Free Survival (mPFS): DeltEx DRI at 13.0 months vs. 6.6 months with SOC (a +97% improvement).
  • Median Overall Survival (mOS): DeltEx DRI, currently at 17.2+ months, compared with 13.2 months for SOC.
  • Durability: 57% of DeltEx DRI patients remained progression-free beyond their expected overall survival based on demographics, compared to just 10% in the control group.
  • Safety Profile: No treatment-related severe adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.

Comments from Leadership

William Ho, CEO and Co-founder of IN8bio, emphasized the critical nature of these results, stating, “GBM is an extremely aggressive brain cancer, with a short median survival of approximately 12 months. The contrast between our repeat-dose DeltEx DRI patients and the SOC controls illustrates a significant improvement in survival outcomes.”

Ho further remarked, “The increase in mPFS is particularly meaningful for newly diagnosed GBM patients, highlighting the potential of our γδ T cell therapy to enhance treatment outcomes.”

Regulatory and Future Outlook

IN8bio aims to utilize funds from its recent financing to engage with the FDA concerning potential clinical pathways, including the feasibility of accelerated approval for the DeltEx DRI therapy.

As part of the ongoing trials, DeltEx DRI has demonstrated a strong safety profile with:

  • No DLTs
  • No cytokine release syndrome (CRS)
  • No immune effector cell-associated neurotoxicity (ICANS)
  • No unexpected infections or SAEs

Long-term Potential of DeltEx DRI

Kate Rochlin, PhD and COO of IN8bio, noted the therapy’s consistent biological response and clinical story. “We observed elevated levels of γδ T cells in circulation and immune activation within tumors, significant for combating this typically hard-to-treat tumor type,” she stated.

The encouraging trends in mPFS and mOS across various clinical centers underscore the reproducibility and scalability of the DeltEx DRI treatment, establishing a solid groundwork for further development.

About IN8bio

IN8bio is at the forefront of developing innovative γδ T cell therapies to address unmet medical needs in oncology and autoimmune diseases. Its lead program, INB-100, targets acute myeloid leukemia, while ongoing research includes the evaluation of combination therapies like the DeltEx DRI for glioblastoma.

For further information, please visit www.IN8bio.com.

Related News